Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants
- 964 Downloads
Purpose of Review
The purpose of this review was to offer practical management strategies for when patients receiving direct oral anticoagulants require elective surgery or present with bleeding complications.
Clinical practice guidelines are now available on the timing of periprocedural interruption of treatment with the newer direct oral anticoagulants based on their pharmacodynamics and pharmacokinetics and based on findings from cohort studies and clinical trials. An antibody that reverses the effects of dabigatran is now available, and a factor Xa decoy is being developed as an antidote to apixaban, betrixaban, edoxaban, and rivaroxaban.
The timing of interruption of direct oral anticoagulants for elective surgery is based on multiple factors, including pharmacologic properties and interactions, the patient’s renal function, and the type of planned surgery. There is little role for low-molecular-weight heparin bridging. Idarucizumab is the treatment of choice for dabigatran-related life-threatening bleeding, while andexanet alfa is being developed to reverse factor Xa inhibitors.
KeywordsDirect oral anticoagulants (DOAC) Reversal Bleeding Surgery Idarucizumab Andexanet alfa
Compliance with Ethical Standards
Conflict of Interest
Dr. Scott Kaatz has received research funding from Janssen; Speaker honorarium from Janssen, Boehringer-Ingelheim, Bristol Myer Squibb, Pfizer, CSL Behring, and Daiichi Sankyo; and consultant fees from Boehringer Ingelheim, Bristol Myer Squibb, Pfizer, Janssen, Daiichi Sankyo, Portola and Roche.
Dr. Charles E. Mahan has received speaker honoraria from Janssen, Bristol Myer Squibb, Pfizer, Portola, and Boehringer Ingelheim; and consultant fees from Janssen, Pfizer, Portola, and Daiichi Sankyo.
Drs Asaad Nakhle, Kulothungan Gunasekaran, Mahmoud Ali, Robert Lavender, and David G. Paje have nothing to disclose.
Human and Animal Rights and Informed Consent
This review article did not involve human or animal experimentation.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126:343–8.CrossRefPubMedGoogle Scholar
- 4.Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;129:1850–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.• Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41:206–32. Guidance from the Anticoagulation Forum on periprocedural interruption of DOACs and nice graphic on the mechanism of P-gp inducers and inhibitors. CrossRefPubMedPubMedCentralGoogle Scholar
- 6.• Doherty JU, Gluckman TJ, Hucker WJ, Januzzi JL Jr, Ortel TL, Saxonhouse SJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017;69:871–98. Expert consensus guidance from the American College of Cardiology on periprocedural interruption of DOACs. CrossRefPubMedGoogle Scholar
- 11.Pharmaceuticals P. Inc. Betrixaban [package insert]. Portola Pharmaceuticals, Inc: South San Francisco, CA; 2017.Google Scholar
- 12.Boehringer Ingelheim Pharmaceuticals, Inc. Dabigatran [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012.Google Scholar
- 13.Bristol-Myers Squibb Company. Apixaban [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2012.Google Scholar
- 14.Daiichi Sankyo Co. Edoxaban [package insert]. Tokyo: Daiichi Sankyo Co.; 2015.Google Scholar
- 15.Janssen Pharmaceuticals. Inc. Rivaroxaban [package insert]. Janssen Pharmaceuticals, Inc: Titusville, NJ; 2011.Google Scholar
- 17.Kumar S, Danik SB, Altman RK, Barrett CD, Lip GY, Chatterjee S, et al. Non-vitamin K antagonist oral anticoagulants and antiplatelet therapy for stroke prevention in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiol Rev. 2016;24:218–23.CrossRefPubMedGoogle Scholar
- 19.Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2016.Google Scholar
- 23.Glund S, Reilly P, van Ryn J, Stangier J. Authors’ reply to Kamel et al.: “effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study”. Clin Pharmacokinet. 2017;56:209–10.CrossRefPubMedGoogle Scholar
- 26.Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113:625–32.CrossRefPubMedGoogle Scholar
- 28.Island Peer Review Organization, Inc. MAPPP (Version 1.1.2) [Mobile application software]. 2017. http://mappp.ipro.org. Accessed 5 July, 2017.
- 29.Narouze S, Benzon HT, Provenzano DA, Buvanendran A, De Andres J, Deer TR, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2015;40:182–212.CrossRefPubMedGoogle Scholar
- 30.Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e326S–e50S.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.National Kidney Foundation. eGFR Calculators (Version 2.3) [Mobile application software]. 2015. https://www.kidney.org/apps/professionals/egfr-calculator. Accessed 5 July, 2017.
- 40.Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.CrossRefPubMedGoogle Scholar
- 41.van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12:320–8.CrossRefPubMedGoogle Scholar
- 42.Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of A. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:2119–26.CrossRefPubMedGoogle Scholar
- 49.• Pollack CV, Jr., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017. Full report of the idarucizumab reversal of dabigatran study. Google Scholar
- 51.• Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–41. Interim report of the andexanet alfa reversal of factor Xa inhibitor study CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Perlstein I, Wang ZQ, Song Y, Wang J, Bedford B, Chang M, et al. Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects [abstract]. Blood. 2014;124:345.Google Scholar
- 55.Dager WE, Roberts AJ, White RH. Urgent reversal of direct acting oral anticoagulant effects with low (< 15 units/kg) or moderate dose (15 to 25 units/kg) FEIBA in 34 patients with major bleeding [abstract]. Am J Hematol. 2016;91:E394.Google Scholar